Education
About Us
Working with TipRanks
Follow Us
Milestone Scientific (MLSS)
:MLSS
Top Page
Milestone Scientific
(MLSS)
Select Model
Select Model
Rating:41Neutral
Price Target:
$0.33
▲(0.30% Upside)
Milestone Scientific's overall stock score is primarily impacted by its poor financial performance, including negative profitability and cash flow issues. The technical analysis and valuation also reflect challenges, while the earnings call provided some positive sentiment. However, the non-compliance notice from NYSE adds significant risk.
Positive Factors
Cost Management
Effective cost management and operational restructuring indicate a focus on improving efficiency and profitability, which is crucial for long-term sustainability.
Medicare Payment Rate Assignments
Securing Medicare payment rates enhances the marketability of the CompuFlo system, potentially increasing adoption and revenue in the medical segment.
International Expansion
International expansion efforts, particularly in the dental segment, can drive revenue growth and reduce reliance on domestic markets, providing a buffer against local economic challenges.
Negative Factors
Negative Profitability
Persistent negative profitability and return on equity highlight operational inefficiencies and challenge the company's ability to generate shareholder value.
NYSE Non-Compliance Notice
The risk of delisting from NYSE poses a significant threat to investor confidence and access to capital markets, potentially impacting long-term growth prospects.
Cash Flow Challenges
Ongoing cash flow challenges limit the company's ability to invest in growth opportunities and may necessitate external financing, impacting financial stability.
Milestone Scientific (MLSS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$25.18M
Dividend YieldN/A
Average Volume (3M)172.66K
Price to Earnings (P/E)―
Beta (1Y)0.77
Revenue Growth0.59%
EPS Growth-39.76%
CountryUS
Employees17
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)-0.01
Shares Outstanding78,628,914
10 Day Avg. Volume233,274
30 Day Avg. Volume172,658
Financial Highlights & Ratios
PEG Ratio0.43
Price to Book (P/B)13.13
Price to Sales (P/S)8.88
P/FCF Ratio-26.14
Enterprise Value/Market Cap2.07
Enterprise Value/Revenue5.73
Enterprise Value/Gross Profit7.87
Enterprise Value/Ebitda-7.59
Forecast
1Y Price Target
$1.00Price Target Upside203.03% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Milestone Scientific Business Overview & Revenue Model
Company DescriptionMilestone Scientific Inc. (MLSS) is a technology-driven company specializing in the development and commercialization of innovative injection technology for the medical and dental industries. The company's flagship products include the CompuFlo® and Wand® systems, which are designed to provide precise and pain-free injections for patients. Milestone Scientific operates primarily within the healthcare sector, focusing on improving patient comfort and outcomes through advanced technologies.
How the Company Makes MoneyMilestone Scientific generates revenue primarily through the sale of its proprietary injection technology systems and disposable products. Key revenue streams include direct sales of the CompuFlo® and Wand® systems to dental and medical practitioners, as well as recurring revenue from disposable cartridges and accessories required for these systems. Additionally, the company may engage in strategic partnerships with healthcare providers and distributors to expand its market reach. Factors contributing to its earnings include the growing demand for pain management solutions in medical and dental procedures, as well as potential licensing agreements for its technology.
Milestone Scientific Earnings Call Summary
Earnings Call Date:Nov 13, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:Mar 27, 2026
Earnings Call Sentiment Positive
The earnings call reflected a positive sentiment due to successful cost management and strategic initiatives in the Dental segment, alongside progress in securing Medicare payment rates for CompuFlo. However, challenges remain in achieving domestic revenue growth and executing a broader commercial rollout of CompuFlo.Q3-2025 Updates
Positive Updates
Cost Reduction and Operational Restructuring
Reduced operating expenses by over $0.5 million compared to the same period last year, while maintaining stable revenue performance. These results reflect the early benefits of the company's transformational strategy.
Expansion in Dental Segment
Expanded direct sales programs in North America and advanced international registrations for the STA Single Tooth Anesthesia System. International dental sales increased year-over-year, partially offsetting the decline in domestic revenue.
Medicare Payment Rate Assignments for CompuFlo
CompuFlo system secured Medicare payment rate assignments under CPT Code 0777T in 3 jurisdictions, supported by 2 MACs, Novitas and First Coast, including states like New Jersey, Texas, and Florida.
Stable Revenue and Positive Outlook
For the 3 months and 9 months ended September 30, 2025, revenue was $2.4 million and $6.9 million, respectively, compared to $2.5 million and $6.6 million for the same period in 2024. Gross profit remained stable.
Negative Updates
Decline in Domestic Dental Revenue
Despite the increase in international dental sales, there was a decline in domestic revenue, highlighting challenges in the home market.
Challenges in Broader Commercial Rollout
The company is cautious about a broader commercialization of CompuFlo, indicating that a more extensive rollout may take additional time and focus.
Supply Chain and Tariff Concerns
Although tariffs are not currently impacting significantly, there is a need to consider a bonded warehouse in the U.S. if tariffs continue to persist.
Company Guidance
During the Milestone Scientific Third Quarter 2025 Financial Results and Business Update Call, the company provided several key metrics and guidance on their progress and future strategy. For the third quarter ending September 30, 2025, Milestone Scientific reported revenue of $2.4 million, slightly down from $2.5 million in the same period of 2024, while the revenue for the first nine months of 2025 was $6.9 million, showing an increase from $6.6 million in the previous year. The company successfully reduced operating expenses by over $0.5 million compared to the same period last year, highlighting their focus on cost management and operational restructuring. Gross profit remained stable at approximately $4.9 million for the first nine months of both 2025 and 2024. The company emphasized its transformational strategy centered around streamlining operations, enhancing commercial execution, and advancing its reimbursement and payer strategy, particularly for the CompuFlo system in the medical segment. Additionally, the organization reported having $1.3 million in cash and cash equivalents and a working capital of approximately $3.1 million as of September 30, 2025.Milestone Scientific Financial Statement Overview
Summary
Milestone Scientific faces significant financial challenges. Despite a strong gross profit margin, the company operates at a loss with negative net profit and cash flow margins. The balance sheet shows low leverage but a concerning negative return on equity. Overall, financial health is weak, necessitating operational improvements.Income Statement
Milestone Scientific's income statement reveals a challenging financial position. The company has experienced a slight revenue growth of 5.45% in the TTM period, but it continues to operate at a loss with a negative net profit margin of -61.16%. The gross profit margin is relatively strong at 74.37%, indicating efficient cost management in production. However, the negative EBIT and EBITDA margins highlight ongoing operational inefficiencies and high operating expenses.35
Negative
Balance Sheet
The balance sheet shows a low debt-to-equity ratio of 0.07, suggesting a conservative approach to leveraging. However, the return on equity is negative at -82.73%, indicating that the company is not generating sufficient returns on shareholders' investments. The equity ratio stands at 41.48%, reflecting a moderate level of financial stability, but the overall negative ROE is a significant concern.40
Negative
Cash Flow
Cash flow analysis indicates significant challenges, with a negative operating cash flow and free cash flow. The free cash flow growth rate is positive at 93.82%, but this is from a negative base, indicating volatility. The operating cash flow to net income ratio is negative, suggesting that the company struggles to convert its accounting profits into cash. The free cash flow to net income ratio is slightly above 1, indicating that free cash flow is in line with net income, albeit both are negative.30
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 9.08M | 8.63M | 9.83M | 8.81M | 10.30M | 5.44M |
| Gross Profit | 6.61M | 6.43M | 6.79M | 4.90M | 6.31M | 3.62M |
| EBITDA | -6.86M | -6.72M | -7.04M | -8.76M | -7.30M | -7.36M |
| Net Income | -6.97M | -4.71M | -6.93M | -8.71M | -6.82M | -7.34M |
Balance Sheet | ||||||
| Total Assets | 8.05M | 9.80M | 11.37M | 13.70M | 19.81M | 19.57M |
| Cash, Cash Equivalents and Short-Term Investments | 1.27M | 3.26M | 5.95M | 8.72M | 14.76M | 14.22M |
| Total Debt | 1.09M | 349.05K | 395.98K | 497.04K | 586.59K | 942.60K |
| Total Liabilities | 4.71M | 3.96M | 3.36M | 3.70M | 3.59M | 3.46M |
| Stockholders Equity | 3.34M | 5.83M | 8.01M | 10.23M | 16.37M | 16.20M |
Cash Flow | ||||||
| Free Cash Flow | -5.26M | -2.93M | -5.33M | -6.04M | -4.03M | -7.01M |
| Operating Cash Flow | -5.26M | -2.92M | -5.33M | -6.03M | -4.02M | -6.98M |
| Investing Cash Flow | -2.98M | 2.97M | -2.97M | -8.53K | -15.19K | -21.44K |
| Financing Cash Flow | 789.19K | 233.77K | 2.56M | -8.54K | 4.57M | 19.71M |
Milestone Scientific Technical Analysis
Negative
0.33
Price Trends
0.38
Negative
0.47
Negative
0.67
Negative
Market Momentum
>-0.01
Negative
41.94
Neutral
21.35
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MLSS, the sentiment is Negative. The current price of 0.33 is below the 20-day moving average (MA) of 0.34, below the 50-day MA of 0.38, and below the 200-day MA of 0.67, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 41.94 is Neutral, neither overbought nor oversold. The STOCH value of 21.35 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MLSS.
Milestone Scientific Risk Analysis
Milestone Scientific disclosed 34 risk factors in its most recent earnings report. Milestone Scientific reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Milestone Scientific Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | $53.45M | 36.42 | 16.29% | ― | 32.36% | ― | |
52 Neutral | $31.48M | -4.80 | -57.98% | ― | 13.67% | -37.01% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $50.36M | -1.20 | -376.23% | ― | 63.53% | 12.49% | |
46 Neutral | $24.61M | -3.69 | -8.05% | ― | -0.95% | 58.17% | |
43 Neutral | $17.38M | -4.28 | -58.34% | ― | 73.38% | 34.87% | |
41 Neutral | $25.18M | -3.87 | -136.47% | ― | 0.59% | -39.76% |
* Healthcare Sector Average
MLSS
Milestone Scientific
0.32
-0.55
-63.22%
RVP
Retractable Technologies
0.82
0.20
32.26%
POCI
Precision Optics Corporation
4.08
-0.92
-18.40%
NEPH
Nephros
5.03
3.55
239.86%
FEMY
Femasys
0.86
-0.21
-19.63%
NXGL
NexGel Inc
1.62
-3.04
-65.24%
Milestone Scientific Corporate Events
Executive/Board Changes
Milestone Scientific Director Leonard Osser Resigns
Neutral
Nov 13, 2025
On November 7, 2025, Leonard A. Osser resigned as a director of Milestone Scientific Inc., but will continue his involvement through an employment and consulting agreement. This change in leadership may impact the company’s operations and stakeholder relations, as Mr. Osser remains connected to the company in a different capacity.
Delistings and Listing ChangesRegulatory Filings and Compliance
Milestone Scientific Faces NYSE Non-Compliance Notice
Negative
Oct 14, 2025
On October 8, 2025, Milestone Scientific Inc. received a notice from NYSE American LLC indicating non-compliance with certain listing standards. The company must submit a compliance plan by November 7, 2025, to maintain its listing, with potential delisting if standards are not met by April 8, 2027.
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.